SeaStar Medical (ICU) FDA Approval Issues Case

• $ICU stockholders filed a claim against SeaStar Medical for overstating FDA approval chances for SCD and hiding financial issues.

• After the news in May 2023, $ICU dropped by over 30%.

• SeaStar investors can join this case to be notified about potential recovery.

Case Details:

After the merger, SeaStar Medical told investors that its lead product, the Selective Cytopheretic Device, was on track for FDA approval.

The company claimed it had met all the requirements for a Humanitarian Device Exemption, which would speed up the approval process for treating rare conditions.

However, in May 2023, the FDA rejected the application.

After the news, $ICU dropped by over 30%.

Based on these events, $ICU investors filed a claim against SeaStar Medical, accusing the company of the following:

• SeaStar overstated the likelihood of FDA approval for its key product, the SCD.

• The company concealed serious financial reporting issues, leading to the need for restatements.

Considering all the representations, investors suspect SeaStar Medical overstated FDA approval chances for SCD and hid financial issues.